This is exactly the problem I have with people like golf.paul. His posts don't really bother me in regards to "bashing". I've always thought that term was silly for these boards, as if the 20 or so people who hang out on any board on avg actually are going to fluctuate the price. It's more that it's just weird and kind of unnerving to imagine a real person typing his posts.
Usually you don't think about it since that's just part of the Yahoo boards...but when you take a second to realize that there really is an adult out there writing things like he does....don't know, it's just strange.
If you think thousands of people are dying because imaginary "wonder drugs" are held up in red tape, you are an idiot. This is exactly why this bill is being pushed by know nothing morons and is opposed by most respectable academicians.
Yeah...that last reply from them was far out in left-field and an awkward attempt at sounding condescending without actually saying anything relevant.
Small-cap biotech's are valuation plays. Listening to someone talk about revenue streams as a relevant fundamental for a company in Phase I/II trials and a market cap of less than $100m is strange. The game is valuation, simple.
Unrelated note, CUR is an Israeli company o.0? Maybe losing my memory, but I don't remember ever hearing about roots in Israel.
Highly unlikely. You have to keep in mind that CUR was around $1.00 even at the start of their Phase II, not their 0.40 period, and the run to $4 took about a year. Additionally, this is an entirely different market this year. CUR made its run in the middle of the escalating IBB euphoria last year. Now we're seeing investors are reacting conservatively to positive news updates, likely after the one-two biotech sell-off punches of the Nov govt shut down and the Sovaldi debacle. Events that would have been huge gains last year are getting a fraction of that this year.
Long BCLI, but no there is no way that this is going to appreciate anywhere near 800% in value in the short term. $150-$200mil market cap is optimistically possible the near term with some positive events, but the numbers you'd need to avoid a split for uplist are highly unlikely. The split will happen and life will go on, I think a lot of people here are overestimating the effect that a reverse-split will have when a company does it for positive reasons.
Weird, shouldn't you be busy on the CUR board asking for advice on if you should invest in BCLI?
Actually curious, do you think your posts here do anything to the share price? I could understand if you were actually doing a good job of subtly bashing, but the stuff you right is so out in left-field and hyperbolic that it just looks stupid. If you want to be good at bashing, why not write an actual nuanced argument against the company?
Coming from a group of investors who are currently spamming a cancer hospitals Facebook page that is used by patients to get information? Haha classic, moral high ground is definitely with you idiots.
You board pumpers are so pathetic. The inclusion criteria REQUIRES that you had SOC, the only exclusion criteria is for heavily treated patients for DC direct, which is far beyond SOC. Congratulations on lying about something that can be found online in ~30 seconds.
Haha also the idea that you could get enrolled for a trial and be treated "hours" after on the same is a joke. Right, no ramp up period, no blood work, no anything. Real heart-warming fake story about having to travel to Europe ya got there ;)
Haha Yahoo Message Board pretend scientists never cease to entertain. First, your answer is largely incoherent as the concept is effectively the same as ALS: paracrine signaling - increase health of local cells- increase myelination activity of oligodendrocytes. Second, they have already tested MSCs and effects of neurotrophins in multiple sclerosis and saw a phenotype, so again your comment is baseless.
He didn't do "the same thing" moron. PRE-PLANNED data releases, it says right in the #$%$ statement from MD Anderson, that's what's considered acceptable practice for the field.
CHERRY PICKING individual patients and releasing information about them as case reports is so far from this that it's hilarious you losers don't understand it.
Wow, the entire country?! Where can I find that press release?? That doesn't sound like hyperbole, or a pathetic misunderstanding of what compassionate use programs are, at all!
You're a %$&*%$# idiot, scary big pharma are the ones who are pouring cash into immunotherapy right now, which if successful will result in all the EXACT SAME idiotic hypothetical scenarios you just went through.
How are you this stupid? Big pharma is both funding immunotherapy AND not funding immunotherapy because it will bankrupt them? Yeah, makes sense.
The same way that "Big Pharma" didn't want to see Juno succeed?
Or the same way "Big Pharma" doesn't want to see Moderna succeed?
Orrrr the same way "Big Pharma" doesn't want to see Bind succeed?
Weird, because "Big Pharma" threw tons of money at those companies to help them succeed with what would be transformative platforms, but I guess NWBO is just the poor victim of "Big Pharma" plotting!
You people are idiots.
Are you #$%$? This is the exact same thing he just pointed out. This was a data release by Sunesis at the AACR meeting. Clinical trial updates at AACR and ASCO are standard for the field. If you don't understand the difference between the NWBO press releases, and the PEER-REVIEWED DATA PRESENTATION AT AN INTERNATIONAL CONFERENCE that you just posted, then you might want to consider getting out of biotech investing altogether.
Got it, so MD Anderson is plotting against NWBO too apparently as that statement is a quote from them.
Keep it up cultists, let the NWBO woo rock you to sleep.
Haha are you idiots for real? Yup, ANYONE who disagrees with your investment thesis is a "paid schill", how convenient that fictional reality must be for you.
"Dr. Buzdar has no associations or financial interest with this company or any other pharmaceutical company. Nor does he serve as a consultant or scientific advisor for any company."
Oh let me guess, MD Anderson is lying to now, as well as the NCI, NIH, and IRS. So many schills after NWBO!
Well you clearly didn't seeing as BCHSP made a reply claiming it wasn't in the video. Let me know when you actually have something useful to add to a conversation or when you at least can understand basic videos like that above.
Negative. "Repurposing drugs" in the context you're thinking of refers to a push from the FDA to take compounds that have been used for years with an established safety profile and try them in other indications. Not a similar situation at all.
I think the misunderstanding over what a Phase I actually is powered to show is why so many people here don't understand both the medical communities and the FDAs opposition to the Right to Try laws. Phase I trials do not establish longitudinal safety, what they establish is a basis for knowing if the drug causes any immediate serious adverse events and what the dose limiting toxicities are for that agent. Alzheimer's patients are an entirely different patient population with their own clinical risks and their own efficacy metrics. I honestly can't say I see where people are getting the idea that you could somehow skip a DLT study in elderly patients in a neurological indication, but again this is what I mean when I say posters around here have gone to the woo-side.